Journal of cardiothoracic and vascular anesthesia
-
J. Cardiothorac. Vasc. Anesth. · Jun 2000
Randomized Controlled Trial Clinical TrialVolume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass.
To compare the hemodynamic efficacy of a new hydroxyethyl starch (HES) preparation (130/0.4) with an HES 200/0.5 solution. ⋯ The new 6% HES 130/0.4 was as effective as a 6% HES 200/0.5 preparation in regard to hemodynamic efficacy. No negative side effects on organ function were seen. The 6% HES 130/0.4 solution may become an alternative strategy for volume therapy in cardiac surgery.
-
J. Cardiothorac. Vasc. Anesth. · Jun 2000
Randomized Controlled Trial Clinical TrialEffects of hemofiltration on serum aprotinin levels in patients undergoing cardiopulmonary bypass.
To determine the effects of hemofiltration on serum aprotinin levels during cardiopulmonary bypass (CPB) surgery. ⋯ Hemofiltration during CPB did not significantly alter serum aprotinin levels in patients receiving half-Hammersmith and full-Hammersmith dosing regimens of aprotinin.
-
J. Cardiothorac. Vasc. Anesth. · Jun 2000
ReviewMyocardial injury in cardiac surgery: the role of transfusion.
The approach to minimizing transfusion therapy in the cardiac surgical patient entails an understanding of the unique physiology of CPB. A comprehensive blood conservation program will promote autologous reinfusion techniques and pharmacologic agents that preserve hemostasis. ⋯ The use of technologies and drugs that attenuate inflammation will reduce consumption and the activation of leukocytes and platelets. This approach should be a multifaceted one that will ultimately lead to better preservation of end-organ function after cardiac surgery.